Chunyu Li

Prof. Chunyu Li

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2025 in Journal of Pharmaceutical Analysis
Verified
Journal Article
Open access
MYMeijun Yue
Meijun Yue
YLYanlu Liu
Yanlu Liu
XFXiaoan Feng
Xiaoan Feng
BCBo Cao
Bo Cao
XFXiaofei Fei
Xiaofei Fei
CLChunyu Li
Chunyu Li
Flavonoids, the key active compounds in Epimedii Folium, have both protective and toxic effects on the liver. Their hepatoprotective effects are associated with reducing lipid accumulation and oxidative stress, which contribute to the management of various liver conditions. In contrast, the mechanisms driving Epimedii Folium-induced hepatotoxicity are less understood but likely involve oxidative stress and pyroptosis. Pharmacokinetic studies, especially on icaritin, indicate that it undergoes isopentenyl dehydrogenation, glycosylation, and glucuronidation in vivo, contributing to its pharmacological effects. However, intermediate metabolites of icaritin may interact with biomolecules, potentially leading to liver toxicity. This review offers a detailed examination of the dual effects of Epimedii Folium flavonoids on liver function, emphasizing recent discoveries in their hepatoprotective and hepatotoxic pathways. We also summarize and discuss the pharmacokinetics of these flavonoids, highlighting how their metabolism affects therapeutic efficacy and toxicity. Lastly, we propose strategies to mitigate liver injury, providing new perspectives on the safe use of Epimedii Folium.

1 November 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
BCBo Cao
Bo Cao
HXHuijuan Xie
Huijuan Xie
JXJing Xu
Jing Xu
NYNuoxian Yu
Nuoxian Yu
ZMZhuo Man
Zhuo Man
LHLi Han
Li Han
Background: Immune checkpoint inhibitor (ICIs)-associated cardiotoxicity is a significant cause of immune-related adverse events and mortality in cancer immunotherapy, lacking effective preventative or therapeutic strategies. Xihuang Pill (XHW), a traditional Chinese medicine with established anti-inflammatory properties and clinical use in cancer treatment and adverse event mitigation, merits investigation for its efficacy against ICIs-induced cardiac toxicity. Purpose: To investigate XHW’s therapeutic effects on Immune checkpoint inhibitors (ICIs)-associated cardiotoxicity and its underlying mechanisms. Methods: This study utilized mass spectrometry technology to identify the chemical components in XHW. The experimental model for ICIs-associated myocarditis was generated in BALB/c mice by immunizing them with murine cardiac troponin I (cTnI) peptide and administering anti-programmed death 1 (PD-1) antibodies to mice. Mice received varying XHW dosages (0.39, 0.78, and 1.56 mg/kg). Myocardial contractility and plasma cardiac injury markers (CK, CK-MB) were assessed. Metabolomics and transcriptomics identified key signaling pathways modulated by XHW, validated via real-time quantitative PCR (QT-PCR). In addition, a correlation analysis was conducted between key genes and differential metabolites. Results: Mass spectrometry identified 171 components in XHW. Pharmacological studies demonstrated that XHW improved cardiac contractility, reduced plasma cardiac injury biomarkers, and attenuated myocardial injury in the myocarditis model. Integrated metabolomic and transcriptomic analyses revealed that XHW primarily modulates the HIF-1 signaling pathway, significantly upregulating HIF-1 mRNA expression and downregulating the mRNA expression of Nppa, Angpt1, Angpt2, and Trf. Correlation analysis identified significant associations between 16 metabolites, including 13-tetradecynoic acid, 1-pentadecanoylglycerol, and arginyl-glycyl-aspartic acid, and these genes. Conclusion: These findings suggest that XHW may alleviate ICIs-associated myocarditis via HIF-1 signaling pathway, offering a promising therapeutic approach for ICIs-related cardiotoxicity.

18 November 2025 in Chinese Journal of Integrative Medicine
Verified
Journal Article
Closed access
PDF file
NYNuo-Xian Yu
Nuo-Xian Yu
MLMeng-Meng Lin
Meng-Meng Lin
JXJing Xu
Jing Xu
BCBo Cao
Bo Cao
JYJia-Hui Yang
Jia-Hui Yang
CLChunyu Li
Chunyu Li

14 June 2026 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
JYJiahui Yang
Jiahui Yang
XLXintong Liu
Xintong Liu
LFLinlin Fan
Linlin Fan
SQShuya Qi
Shuya Qi
CLChunyu Li
Chunyu Li
GLGuo-hui Li
Guo-hui Li

18 June 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JYJie Yang
Jie Yang
HZHongying Zhou
Hongying Zhou
XMXiao Ma
Xiao Ma
XZXuelin Zhou
Xuelin Zhou
SWshizhang wei
shizhang wei
CLChunyu Li
Chunyu Li
Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease with an increasing incidence. The complex pathogenesis of AIH poses significant challenges for clinical treatment. In recent years, with the introduction of cutting-edge concepts such as “immune–metabolic interplay” and “intercellular communication networks,” along with novel detection methods and technologies, research on the pathogenesis of AIH has shifted from a single-molecular-mechanism perspective to a systematic regulatory network analysis. This shift has not only provided more research evidence for a deeper understanding of the molecular biological mechanisms underlying AIH but also offers a potential reference for the development of targeted therapeutic drugs for AIH based on novel targets. Therefore, this review starts with aberrant activation signals from key immune cells—including dendritic cells (DCs), macrophages (Mφ), and T/B cells—and integrates the intercellular signaling communication mechanisms between hepatocytes, cholangiocytes, and immune cells to systematically summarize the key molecular biological mechanisms and targets identified in recent years, providing a reference for future elucidation of the critical mechanisms of AIH. On this basis, the review further integrates the current application and research progress of clinically used AIH therapeutic drugs, as well as those at various stages of development, including potential therapeutic compounds. It discusses the limitations of current clinical drugs and evaluates the feasibility and future application potential of potential compounds for AIH treatment in preclinical and clinical studies, thereby offering comprehensive research evidence for the management of AIH.

10 December 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
NYNuoxian Yu
Nuoxian Yu
BCBo Cao
Bo Cao
JYJiahui Yang
Jiahui Yang
JXJing Xu
Jing Xu
MZMingyu Zhang
Mingyu Zhang
GLGuo-hui Li
Guo-hui Li